Pannexin therapeutics company

An innovative drug development program in epilepsy based on Pannexins blockade

Epilepsy carries a huge burden. 

Epilepsy affects 50 million subjects worldwide and is the most common neurological condition. 

Epilepsy has devastating consequences: it affects cognition, particularly learning and memory, disrupts socio-professional & family interactions, causes many co-morbidities including psychiatric conditions. Developmental consequences of a pediatric epilepsy are carried life long.

Epilepsy kills: 3-6 times the mortality rate of general population.

Epilepsy is still not optimally treated. 

  • Epilepsy carries on stigma

  • Epilepsy is not controlled by current anti epileptic drugs in 1/3 of patients

  • Current therapies have significant side effects

Committed to develop 

new anti epileptic drugs

Research on human epilepsies rather than animal models of seizures

PannTheraPi aims at addressing epilepsy therapy via breakthrough approaches

Focus on targets: 

  •   specific of epilepsy
  • at play at seizure generation rather than at basal state


PannTheraPi has developed an innovative research platform based on human epileptic postoperative tissue

Discovery platform

PannTheraPi IP property

Unravel new & specific epilepsy mécanismes

Human postoperative epileptic tissues

Innovative drug candidates

Patients with 



drug product

In vitro cells

Isolated targets

Screening platform

PannTheraPi expertise



Ex vivo



Non clinical, ADME, CMC, clinical studies / regulatory, market strategies



Efficacy on

animal models

In vivo 




Pannexin-1 contributes to seizure generation

  •   In human epileptic brain tissue 
  •   In a representative mouse model of Epilepsy

Pannexin-1 is related to the epileptic condition

  • Poorly expressed in healthy tissue
  • Highly expressed in pathological tissue

Pannexin-1 opens during the seizure initiation process

Pannexin-1 blocker drug is a specific therapy

State-dependent activity

Prevents seizures

Does not affect basal brain behaviors

Dossi et al. Science Transl Med 2018

Michalski et al. Elife 2020

Development of 

Pannexin-1 blockers

  • To treat epilepsy
  • Acting on the cause of the disease rather than symptoms
  • An innovative target: THE PANNEXIN-1 CHANNEL
  • A specific target in the central nervous system
  • A safe and effective target for new drugs as demonstrated in representative preclinical models


Co-founder - CEO

Clinical neuropsychopharmacologist

  • >30 years of experience in the pharma and biotech industries
  • Expert in the pharmaceutical development of innovative therapeutic products in the field of the CNS and rare diseases
  • Previous positions at Advicenne (Founder, Chairman & CEO), FORENAP Parma, Eli Lilly & Co, Synt:em


Co-foudner - COO


  • >12 years of experience in the biotech and medtech industries
  • Transversal development of medical products from research to late clinical stage in the field of the CNS and rare diseases
  • Previous positions at Medday Pharmaceuticals, Gecko Biomedical (Tissium), Advicenne, Auris Medical & Medesis

Nathalie ROUACH, PhD  

Co-founder - Scientific consultancy


  • 1st class Research Director at Inserm/  Head of the “Neuroglial Interactions in Cerebral Physiology and Pathologies” Laboratory (College de France/ PSL, Paris) 
  • Expert in the field of connexins and pannexins in the context of neuroglial interactions with an Innovative multidisciplinary approach 
  • Numerous Awards and distinctions since 2006 (including ERC Award in 2015)


Co-founder - Medical consultancy

Neurologist & Neuroscientist

  • Associate Professor at Sorbonne University (Paris) / Practitioner at the Department of Clinical Neurophysiology at the Pitié-Salpêtrière hospital (APHP, Paris)
  • Expert in epilepsy and neurobiology of epilepsy
  • Dedicated group to electrophysiology (human and animal brain tissues)
  • ERC Awards in 2019